Von Hippel-Lindau Tumor Suppressor (VHL) Antikörper

Antigen: Von Hippel-Lindau Tumor Suppressor (VHL)

Synonyme: RCA1, VHL1, HRCA1, Vhlh, BcDNA:RH61560, VHL, d-VHL, dVHL, dmVHL, Dmel\CG13221, CG13221, rca1, vhl1, hrca1, zgc:158722, DKFZp469K2019

Klonalität: Monoklonal (Ig33)

Wirt: Maus

Reaktivität: Human

Applikation: Western Blot (WB)

Produktnummer: ABIN306858

Produktbeschreibung

Weitere Bezeichnung: von Hippel-Lindau Protein

Isotyp: IgG1  (Passende Sekundärantikörper)

Klon: Ig33

Beschreibung: It recognizes a protein of 30kDa which is specifically identified as von Hippel-Lindau protein (VHL). Epitope of this antibody localizes between amino acids 1-54 as it does not recognize the truncated form of VHL protein. Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group of neoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), and pheochromocytoma. Molecular genetic studies suggest that VHL is a tumor-suppressor gene, correspondingly, reintroduction of a VHL complementary DNA (cDNA) into RCC cells inhibits their ability to form tumors in nude mice. Two transcriptional elongation factors, Elongin B and C, are shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. It is proposed that pVHL functions in vivo as a negative regulator of transcription elongation.

Anwendungen

Applikationshinweise: This antibody can be used for immunoprecipitation (2 ug/mg of protein lysate), Western blotting (1 ug/ml) and immunohistochemistry on frozen and formalin/paraffin embedded tissues (2-4 ug/ml). Positive Control: Carcinomas of kidney, lung, prostate, colon, breast, bladder and thyroid, cerebellar hemagioblastomas and pheochromocytoma.

Konzentration: 1 mg/ml

Lagerung: Product should be stored at -20C. Aliquot to avoid freeze/thaw cycles

Beschränkungen: Nur für Forschungszwecke einsetzbar